Varian Creates Patient Education Web Site

Publication
Article
OncologyONCOLOGY Vol 13 No 1
Volume 13
Issue 1

Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments.

Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments. The site includes information from the National Cancer Institute and leading cancer treatment centers. Varian’s cancer patient education web site is located at www.varian.com/hcs /rad.

Articles in this issue
Varian Creates Patient Education Web Site
M. D. Anderson Researchers to Study Quality of Life in Testicular Cancer Patients
Follow-up Essential for Positive Home HIV Test Results
FDA Treads Delicate Line Between Safety and Speed
Estrogen May Reduce Colorectal Cancer Risk in Postmenopausal Women
Surgeons Issue Consensus Statement on Performing Sentinel Lymph Node Biopsy
Sentinel Lymph Node Mapping in Breast Cancer
Komen Foundation Receives Grant to Develop New Breast Imaging Technology
New Imaging Agent Seems to Enhance Detection of Metastatic Breast Cancer
NCI to Sponsor Phase III Trials of Liquid Shark Cartilage Angiogenesis Inhibitor
Aspirin Decreases Genetic Mutations Associated With Inherited Colon Cancer
Open Lung Biopsy Cost-Effective in Evaluating Solitary Pulmonary Nodules
Sentinel Lymph Node Mapping in Breast Cancer
Chemoprevention of Colorectal Cancer: Dietary and Pharmacologic Approaches
Clinical Status and Optimal Use of Amifostine
Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content
Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.

Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC

Russ Conroy
October 12th 2025
Article

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Serplulimab plus chemotherapy also achieved a threefold higher pathological complete response rate and a significant reduction in the risk of recurrence compared with the control arm.

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

Tim Cortese
October 10th 2025
Article

An independent data monitoring committee suggested the submission of an early NDA for serplulimab plus chemotherapy in early-stage gastric cancer.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor-positive GEP-NETs.

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

Roman Fabbricatore
October 10th 2025
Article

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.

Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

OST-HER2 Exhibits Survival Benefit in Pulmonary Metastatic Osteosarcoma

Roman Fabbricatore
October 10th 2025
Article

Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.